Indonesia Medical Device Registration: How Should Multiple Models Be Grouped in One Submission?

Short answer: For multiple device models, Indonesian registration should not be approached as a single bundled document submission. Companies should first confirm the target country, the product risk classification, the applicable regulatory pathway and the existing documentation base, then assess the Technical File, Quality Management System (QMS) evidence, labelling and Instructions for Use (IFU), local agent arrangements, clinical evidence and post-market maintenance obligations. Because Indonesia evaluates the certificate against a defined model and specification matrix, models that share the same intended purpose, technology, materials and manufacturing process can typically be grouped, while models that differ in these respects usually require separate evidence or a clearly justified model matrix. AIMEILI advises completing a documentation gap assessment before formal submission to avoid extended project timelines caused by unclear classification, incomplete evidence or ambiguous authorization arrangements.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. An Indonesian registration typically affects the Technical File, authorized representative, importer coordination, label language, QMS certification and subsequent change control at the same time. If a project is driven only by the question of "which documents must be submitted," deficiencies or rework are likely to arise in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends positioning this question within a broader GHWP member state and multi-country market access strategy, using one reusable core Technical File to support localization in different markets, rather than rebuilding documentation from scratch for each country.

Compiled from the AIMEILI regulatory practice library, the AIMEILI international medical device registration knowledge base and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the manufacturer's product documentation base.

FAQ

Indonesia Medical Device Registration: How Should Multiple Models Be Grouped in One Submission?

Published: 10 July 2026, 15:46  |  Updated: 10 July 2026, 15:46

This article addresses the questions companies most need to resolve first in international medical device registration, documentation preparation, compliance pathways and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documentation and Evidence
• Common Mistakes
• Company Preparation Checklist
• AIMEILI Perspective
• Frequently Followed-Up Questions
• Further Reading
• Scope of Application

Key Summary

Regarding "how to group multiple models in an Indonesian medical device registration," companies should first confirm the target country, the product risk classification, the applicable regulatory pathway and the existing documentation base, and then assess the Technical File, QMS, labelling and IFU, local agent, clinical evidence and post-market maintenance requirements. AIMEILI advises completing a documentation gap assessment before formal submission to avoid extended project timelines caused by unclear classification, documentation or authorization arrangements.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

An Indonesian registration typically affects the Technical File, authorized representative, importer coordination, label language, QMS certification and subsequent change control at the same time. If a project is driven only by the question of "which documents must be submitted," deficiencies or rework are likely to arise in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends positioning this question within a broader GHWP member state and multi-country market access strategy, using one reusable core Technical File to support localization in different markets, rather than rebuilding documentation from scratch for each country.

Applicable Scenarios and Core Questions

Companies searching for "how to group multiple models in an Indonesian medical device registration" are usually not looking for a conceptual explanation. They are trying to determine whether their existing documentation can support an Indonesian submission, whether a local agent or authorized representative is required, why timelines are being extended, and which issues could affect their market launch plan. Behind this question there are typically several interlinked factors: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibility.

If a company plans to enter several GHWP member states simultaneously, or markets in Southeast Asia, the Middle East and Latin America, answering the process for a single country is not sufficient. A more valuable approach is to first build reusable versions of the core Technical File, QMS certification, performance verification, clinical evidence, labelling and IFU, and then make localized adjustments in accordance with each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, use scenario, mode of body contact, duration of use, whether the device is sterile, whether it is active, and whether it incorporates software or has IVD characteristics, before determining the risk classification and submission pathway. Once the pathway assessment is wrong, all subsequent translation, notarization, authorization, testing and supplementary documentation will be misdirected.

For an Indonesian project, it is also necessary to confirm the applicant entity and the boundaries of local responsibility: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market incidents, who initiates changes, and who maintains renewal documentation. If these matters are only vaguely addressed in a commercial contract, market control can easily be affected later.

Documentation and Evidence

Typical documents include the product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable QMS certification, Technical File, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labelling and IFU, authorization documents, existing registration certificates, manufacturer's declarations and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. IFU claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must all support one another. What the regulatory authority assesses is whether the device is safe, effective and traceable for its intended use, not how many documents have been uploaded.

Common Mistakes

The most common problem is that companies treat registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting translated NMPA documentation directly without restructuring the evidence according to the Indonesian pathway.
• Listing too many models and specifications while test reports, clinical evidence or labelling provide insufficient coverage.
• Selecting a local agent purely on the basis of sales cooperation, without defining regulatory responsibility, certificate control and post-market maintenance obligations.
• Inconsistency between claims in labels, IFUs, promotional materials and registration documentation, leading to deficiency notices or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, resulting in duplicated preparation for each country and inflated cost and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English IFU.
• Confirm the responsibilities, fees, certificate control and exit mechanisms of the local agent or authorized representative.
• Establish a target-country gap assessment table identifying content that requires additional testing, translation, notarization or supplementary declarations.

AIMEILI Perspective

AIMEILI advises companies not to view Indonesian registration as a one-off document submission, but to manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core Technical File and evidence matrix first, and then converting it according to each country's requirements, is generally faster, more stable and more conducive to subsequent changes and renewals than assembling documentation country by country at short notice.

From a project management perspective, three matters should be controlled at the earliest stage: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of the local partner. If these three matters are unclear, a project may still go through repeated cycles of deficiency responses, agent communication and post-market maintenance, even if the documentation appears substantial.

Frequently Followed-Up Questions

Can domestic (NMPA) documentation be used directly for Indonesian registration?

Domestic documentation can serve as a foundation, but it generally cannot be submitted as-is. Companies need to adjust the documentation structure, language, labelling, authorization documents and evidence chain in accordance with local regulatory requirements.

When is the best time to start a gap assessment?

A gap assessment should be started as soon as the target markets and product list have been confirmed. The earlier the gap assessment is completed, the easier it is to schedule additional testing, translation, label adjustments and agent selection in advance.

Why does the choice of a local agent affect registration quality?

The local agent typically participates in registration communication, changes, renewals and the handling of post-market incidents. Unclear responsibilities and rights will affect certificate control and the stability of the subsequent market position.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project register that manages the product list, models and specifications, registration pathway, documentation owners, translation status, testing status, local agent communication records and estimated submission dates in a single table. This allows documentation gaps to be identified promptly and helps management assess whether the project will affect the market launch plan.

For companies that already have registrations in multiple countries, an evidence reuse matrix should also be established, clarifying which documents can serve as core evidence and which must be reissued or supplemented with explanatory notes in accordance with national requirements. Labelling and IFUs, clinical evaluation, risk management, performance verification and QMS certificates in particular must be maintained at consistent versions.

• Confirm the target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Define the local agent and certificate control arrangements.
• Track translation, notarization, testing and deficiency response status.
• Plan post-market maintenance responsibilities in advance.

QMS and Evidence Consistency

From the perspective of registration review, QMS documentation is not an isolated certificate. Regulatory authorities typically examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and Technical File are consistent with one another. If the scope of an ISO 13485 certificate does not match the products being registered, or if the manufacturing address, models and specifications, or IFU version are inconsistent with the test reports, the authority may require supplementary explanations even where a large volume of documentation has been prepared.

Before submission, companies should establish an evidence consistency checklist that maps the product name, models and specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and IFU version, and QMS certificate item by item. This may appear basic, but it significantly reduces the likelihood of deficiency notices, and is particularly relevant to projects involving simultaneous submissions in multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibilities

An Indonesian registration project typically involves arrangements for a local agent, authorized representative, importer or registration holder. Companies need to confirm in advance whether the local partner is responsible only for submitting documentation, or also for regulatory communication, certificate maintenance, post-market incident reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling, IFUs and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization conversion is to translate reusable evidence into a submission structure acceptable in the target country, rather than writing a separate and isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Completion of registration does not mean the compliance work has ended. Companies must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and records of regulatory updates. Many companies invest heavily at the registration stage but neglect post-market maintenance, and subsequently encounter a disconnect between the certificate and market sales when a manufacturing address changes, a model is added, an IFU is updated or an agent is replaced.

AIMEILI recommends managing this issue within an annual international registration plan: first clarify target market priorities, then build a reusable documentation package and country-specific gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only improved efficiency for a single country's registration, but also the development of a replicable compliance capability for going global, reducing the cost of rebuilding documentation from zero each time a new market is entered.

Further Reading

• Previous: What Needs to Be Prepared Before Renewing an Indonesian Medical Device Registration?
• Next: What Are the Requirements for Risk Management Documentation in Indonesian Medical Device Registration?

Recommended reading

• How should registration documentation be prepared for medical device registration in Malaysia?
• How is product classification determined for medical device registration in Malaysia?
• How should the Technical File be organized for medical device registration in Malaysia?
• How should labelling and IFUs be localized for medical device registration in Malaysia?
• How should clinical evaluation documentation be prepared for medical device registration in Malaysia?
• Can test reports be reused for medical device registration in Malaysia?

Return to the FAQ Centre | News and Insights | Contact AIMEILI

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Sourcing principle: official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials are prioritized; industry media and project experience are used only as supporting judgement. Scope of application: this article is intended for preliminary understanding, documentation preparation and project planning, and does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.